3.11 USD
▼-0.31-9.06%
盘后 3.48 0.00%
2026-11-20
市值
$23.50M
市盈率
—
EPS
-7.14
股息率
—
52 周区间
2.66 – 70.60
成交量
44.75K
Beta
2.32
目标价
1.50
52W 低 2.6652W 高 70.60
价格走势
公司简介
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb...